HomeInvestors HealthGain slips after early-stage data for Parkinson’s therapy Gain slips after early-stage data for Parkinson’s therapy By BOMAR ENT. August 29, 2024 FacebookTwitterPinterestWhatsApp Gain slips after early-stage data for Parkinson’s therapy Source link Previous articleWhere Will Dutch Bros Stock Be in 5 Years?Next articlePrediction: This ETF Will Soar Over the Rest of the Year latest articles explore more Armed Robbers Gang-Rape Christian’s Wife in Pakistan Dividend Kings and Aristocrats: A History & Guide to Passive Income RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade) Your AI Survival Guide: Scraped Knees, Bruised Elbows, and Lessons Learned from Real-World AI Deployments Investing / Trading Strategy Journal: Improve your outcomes with consistent strategy and performance review – tell yourself the truth about what works and what... Guess? Non-GAAP EPS of $1.48 beats by $0.10, revenue of $932.25M beats by $24.5M LEAVE A REPLY Cancel reply Comment: Please enter your comment! Name:* Please enter your name here Email:* You have entered an incorrect email address! Please enter your email address here Website: Save my name, email, and website in this browser for the next time I comment.